ライフサイエンスコーパス: resveratrol

1 e consensus about the physiological roles of resveratrol.

2 uding the valuable compounds piceatannol and resveratrol.

3 to BLG without ligand or in the presence of resveratrol.

4 330-400nm, respectively, for the analysis of resveratrol.

5 AhR3'DT-1, added the prenyl group to C-3' of resveratrol.

6 r growth in combination with the antioxidant resveratrol.

7 important role in the mechanism of action of resveratrol.

8 vanillic acid, caffeic acid, epicatechin and resveratrol.

9 s, such as catechin, epicatechin, piceid and resveratrol.

10 removal as PVPP, but with lower affinity to resveratrol.

11 rly soluble natural polyphenols curcumin and resveratrol.

12 ucoside, E-piceid, E-epsilon-viniferin and E-resveratrol.

13 enol, is low and negligible when compared to resveratrol.

14 dimension to the physiological mechanism of resveratrol.

15 m 263 or L. fermentum 296), quercetin and/or resveratrol.

16 feeding with chow diet containing vehicle or resveratrol.

17 RC1-dependent signaling and was sensitive to resveratrol.

18 the calibration of catechin, epicatechin and resveratrol.

19 during SIRT1 overexpression or activation by resveratrol.

20 was determined in complex with its substrate resveratrol (1.89 A), its product vanillin (1.75 A), and

21 ood was cultured in the presence of +/-25 uM resveratrol, +/-1 uM curcumin, +/-5 mg/L theophylline, +

22 Here, we show that resveratrol (10 microM, 48 hr) induces both a cell growt

23 ere randomized to receive a daily capsule of resveratrol, 125 mg or 500 mg, or placebo for 6 months.

24 To determine whether resveratrol, 125 mg/d or 500 mg/d, improves the 6-minute

25 Administration of resveratrol, 125 or 500 mg/d, or placebo once daily.

26 hin (482 mug/g), gallic acid (319 mug/g) and resveratrol (29.8 mug/g) in skin of Ghara Shani, quercet

27 s study, we identified a synthetic analog of resveratrol (3,5,4'-trihydroxy-trans-stilbene), termed D

28 the content of stilbene represented by trans resveratrol-3-glucoside was only 18.5-70.5mg/100gdm.

29 wed that postintervention HbA1c was lower on resveratrol (35.8 +/- 0.43 mmol/mol) compared with place

30 This microsomal fraction-derived resveratrol 4-dimethylallyl transferase utilizes 3,3-dim

31 -promoting and disease-limiting abilities of resveratrol, a natural polyphenol, has led to considerab

32 When resveratrol, a pharmacological activator of SIRT1, was d

33 Resveratrol, a polyphenol found in various plant sources

34 Here we show that resveratrol, a polyphenol, significantly induces PP2A ac

35 Research shows that resveratrol, a sirtuin activator in red wine, improves e

36 process that is considered a key feature of resveratrol action is the activation of the nicotinamide

37 tidiabetic drug metformin or the antioxidant resveratrol activated AMPK signaling and inhibited mTORC

38 Maternal resveratrol administration recovers metabolic activity o

39 these data reveal a novel mechanism by which resveratrol alleviates NTHi-induced inflammation in airw

40 aglycones isorhapontigenin, piceatannol, and resveratrol, along with glucose, were released by deriva

41 sent study is to investigate whether and how resveratrol alters basal inhibitory synaptic transmissio

42 e anti-neuroinflammatory activity of a novel resveratrol analog 4-(E)-{(p-tolylimino)-methylbenzene-1

43 m for the inhibition of Stat3 signaling by a resveratrol analog and suggest that the preferential gro

44 -dimethoxystyryl)phenyl acetate (Cmpd1) is a resveratrol analog that preferentially inhibits glioma,

45 Resveratrol and (E)-1,2,3-trimethoxy-5-(4-methoxystyryl)

46 Resveratrol and 6-O-methylalaternin were isolated from t

47 between the ripening ratio and C6 compounds, resveratrol and carbonyl compounds.

48 ific to the peptide sequence, while those of resveratrol and curcumin are non-specific in that they s

49 Resveratrol and curcumin bind only to the hydrophobic re

50 pruning including a strong accumulation of E-resveratrol and E-piceatannol during the first six weeks

51 genes, followed by a rapid accumulation of E-resveratrol and E-piceatannol.

52 Moreover, trans-resveratrol and ellagic acid stand out for their high co

53 trans-Resveratrol and hesperetin combination (tRES-HESP) corre

54 fer or with the small-molecule inducer trans-resveratrol and hesperetin formulation also improved wou

55 egrity genes with the nutraceutical compound Resveratrol and its analog Pterostilbene, linking these

56 ck also contributed to the accumulation of t-resveratrol and most of individual anthocyanins in the '

57 ee had also both the highest levels of trans-resveratrol and piceid, and Muscat de Hambourg the highe

58 Postintervention differences between the resveratrol and placebo arms were evaluated by ANCOVA ad

59 ble from weeks 0 to 5 did not differ between resveratrol and placebo groups.

60 Resveratrol and quercetin are well-known polyphenolic co

61 Additionally, forced degradation studies of resveratrol and quercetin were established and the metho

62 for routine in vitro and in vivo analysis of resveratrol and quercetin.

63 yroxine preferential binding sites, by using resveratrol and radiolabeled T4 as probes.

64 acity was mostly affected by the presence of resveratrol and rutin, while total polyphenolic content

65 The effects of resveratrol and the soy isoflavones genistein and daidze

66 te the interactions of polyphenols with both resveratrol and thyroxine preferential binding sites, by

67 ation was the highly preferential binding of resveratrol and thyroxine, both characterized by negativ

68 st individual anthocyanins, flavonols, trans-resveratrol and total phenolic compounds, and thus, high

69 Resveratrol and valproic acid treatment of one of the CS

70 gallate (EGCG), gallic acid, propyl gallate, resveratrol, and alpha-tocopherol) were investigated for

71 al products, such as terbutaline, fenoterol, resveratrol, and catechin.

72 The multiple-ring compounds, EGCG, resveratrol, and curcumin, redirect Abeta(17-36) from a

73 tionship with the antioxidant activity (AA), resveratrol, and naringin in the fruit from SLP.

74 Apigenin, resveratrol, and piceatannol all induced Nrf2 translatio

75 Nrf2, and this can be modulated by apigenin, resveratrol, and piceatannol.

76 bene to be a weaker inhibitor of CYP3A4 than resveratrol, and stronger than dimethoxy-nitrostilbene.

77 constants for the reaction of MGO with trans-resveratrol, apigenin, kaempferol and fisetin were (2.7

78 he reactions between four polyphenols (trans-resveratrol, apigenin, kaempferol and fisetin) and methy

79 ests a potential anti-restenotic modality of resveratrol application suitable for open surgery.

80 F (% ejection fraction <45) was administered resveratrol ( approximately 320 mg/kg per day).

81 Whilst the protective actions of resveratrol are commonly ascribed to its antioxidant act

82 lying that compounds such as piceatannol and resveratrol are potentially available in what is now ess

83 tuin-activating compounds (dSTACs) including resveratrol are promising drug candidates, their clinica

84 ted mean Matsuda index: 5.18 +/- 0.35 in the resveratrol arm compared with 5.50 +/- 0.34 in the place

85 n, insulin sensitivity was unaffected in the resveratrol arm compared with the placebo arm.

86 was lower in overweight men and women in the resveratrol arm.

87 lection library led to the identification of resveratrol as an inhibitor of MRGPRX2.

88 c acid), piracetam, quercetin, vitamin D and resveratrol as potential longevity promoting compounds,

89 of a class of reported STACs (represented by resveratrol) as direct SIRT1 activators is under debate

90 ives and stilbenes, as trans-piceatannol and resveratrol, as main secondary metabolites.

91 The Nrf2 inducer resveratrol, as opposed to catalase, reversed oxidative

92 Concordantly, resveratrol attenuated Akt phosphorylation in injured ar

93 In addition, we found that resveratrol blocked endocannabinoid-mediated long-term s

94 e we present a 2.1 A co-crystal structure of resveratrol bound to the active site of TyrRS.

95 Nitrostilbene and resveratrol, but not dimethoxy-nitrostilbene, engage ele

96 ication of catechin, epicatechin, quercetin, resveratrol, caffeic acid, gallic acid, p-coumaric acid,

97 out whether the antidiabetic effects of oral resveratrol can act directly on these tissues.

98 uation of the oxygen-labeling pattern of the resveratrol-cleaving CCO, NOV2, previously reported to b

99 Nevertheless, trans-resveratrol competitively inhibited CpLIP2 activity.

100 ry skin anthocyanin and flavonol amount or t-resveratrol concentration in both skins and wines.

101 This study showed that resveratrol could be encapsulated within low-energy nano

102 Precise understanding of trans-resveratrol/CpLIP2 interactions has important implicatio

103 nt and that treatment with SIRT1 activators (resveratrol, curcumin) and agents that prevent NAD deple

104 performed to examine the effect of vanillin, resveratrol, curcumin, and epigallocatechin-3-gallate (E

105 We selected top five ranked phenolics (Resveratrol, Curcumin, Quercetin, Epigallocatechin Galla

106 ntakes over the previous year, and an ad hoc resveratrol database.

107 Here we show for the first time that resveratrol decreases expression of pro-inflammatory med

108 h potential applications in the synthesis of resveratrol derivatives.

109 rnative technique to determine the amount of resveratrol dietary supplements, as a model for more com

110 se, and is specifically blocked in vivo by a resveratrol-displacing tyrosyl adenylate analogue.

111 Resveratrol displayed significant anti-adipogenic activi

112 n of combined epigallocatechin-3-gallate and resveratrol (EGCG+RES) increased energy expenditure and

113 id injury model, periadventitial delivery of resveratrol either via Pluronic gel (2-week), or polymer

114 We report that resveratrol elevated cAMP levels by itself and further p

115 the potential of a formulation comprised of resveratrol, ellagic acid, genistein, curcumin and querc

116 The polyphenolic rings of resveratrol enable it to react with and detoxify otherwi

117 plemented with the SIRT1-activating molecule resveratrol exhibited increased hippocampal SIRT1 activi

118 Resveratrol exhibits a clear amyloid-solubilizing effect

119 Higher habitual dietary resveratrol exposure was associated with lower risk of o

120 Moreover, fecal transplantation from healthy resveratrol-fed donor mice is sufficient to improve gluc

121 Hence, we examined the efficacy of resveratrol for counteracting age-related memory and moo

122 Our observations do not support the use of resveratrol for improving glycemic control.

123 Treatment of MT-COMP mice with aspirin or resveratrol from birth to P28 decreased mutant COMP intr

124 the thermodynamic parameters suggested that resveratrol-gliadin binding mainly occurs through hydrop

125 rol group vs placebo; P = .12 for the 500-mg resveratrol group vs placebo).

126 rol group vs placebo; P = .96 for the 500-mg resveratrol group vs placebo).

127 or the placebo group (P = .18 for the 125-mg resveratrol group vs placebo; P = .12 for the 500-mg res

128 or the placebo group (P = .07 for the 125-mg resveratrol group vs placebo; P = .96 for the 500-mg res

129 g time were 0.5 (2.3) minutes for the 125-mg resveratrol group, -0.6 (2.1) minutes for the 500-mg res

130 alk distance were 4.6 (8.1) m for the 125-mg resveratrol group, -12.8 (7.5) m for the 500-mg resverat

131 veratrol group, -12.8 (7.5) m for the 500-mg resveratrol group, and -12.3 (7.9) m for the placebo gro

132 rol group, -0.6 (2.1) minutes for the 500-mg resveratrol group, and 0.4 (2.1) minutes for the placebo

133 eta(17-36) aggregation is as follows: EGCG > resveratrol > curcumin > vanillin, consistent with exper

134 The presence of trans-resveratrol has a special relevance at light toasting: 1

135 Finally, we show that resveratrol has anti-inflammatory effects post NTHi infe

136 activated toward some specific substrates by resveratrol has been poorly understood.

137 Resveratrol has been reported to lower glycemia in roden

138 Resveratrol has long been thought as an interesting ther

139 otential biological activity of low doses of resveratrol has not been extensively studied and, thus,

140 rition timing and suggest that metformin and resveratrol have therapeutic potential to prevent PTB.

141 Encapsulation of resveratrol improved its chemical stability after exposu

142 Resveratrol improves insulin sensitivity and lowers hepa

143 TORE trial found no consistent evidence that resveratrol improves walking performance in patients 65

144 flavan-3-ols, flavonols, phenolic acids, and resveratrol in blueberry genotypes with fruit color rang

145 methods were valid for the determination of resveratrol in dietary supplements.

146 A rapid analytical approach for the assay of resveratrol in red wines, based on Paper Spray Mass Spec

147 y also give evidence of a promising role for resveratrol in the prophylaxis and therapy of AD.

148 ignificantly blocked by the SIRT1 activator, resveratrol, in osteoblastic UMR 106-01 cells.

149 Resveratrol increased to 7.19+/-0.07microg/g dry weight

150 variety of biochemical assays, we find that resveratrol indeed acts through the ICRF-187 binding loc

151 ions and its ability to induce vasodilation, resveratrol induced oxidative activation of PKG1alpha an

152 sm of resveratrol-induced p53 activation and resveratrol-induced apoptosis by direct targeting of G3B

153 mitochondrial calcium uniport, prevents the resveratrol-induced augmentation in oxidative capacities

154 downstream AMPK pathway partly abolished the resveratrol-induced increase of glucose oxidation.

155 These findings disclose a novel mechanism of resveratrol-induced p53 activation and resveratrol-induc

156 molecular mechanism and direct target(s) of resveratrol-induced p53 activation remain elusive.

157 Depletion of G3BP1 significantly diminishes resveratrol-induced p53 expression and apoptosis.

158 Herein we show that resveratrol ingestion produces taxonomic and predicted f

159 (AoSMCs) with SIRT1 activators (SRT1720 and resveratrol) inhibit both HAS2 expression and accumulati

160 Resveratrol inhibited compound 48/80-induced Tango and M

161 Notably, the polyphenolic phytoalexin resveratrol, inhibited uPAR expression and consequently

162 Furthermore, resveratrol inhibits NTHi-induced ERK1/2 phosphorylation

163 induction or treatment with a SIRT1 agonist, resveratrol, inhibits AR-stimulated proliferation.

164 Maternal resveratrol intervention protects offspring against high

165 Resveratrol is a natural compound found in red wine that

166 Resveratrol is a natural phytoalexin synthesized by plan

167 Resveratrol is a natural polyphenol found in various pla

168 Resveratrol is a polyphenol that ameliorates the product

169 Resveratrol is a promising anti-restenotic natural drug

170 Resveratrol is a stilbene, which is one of a group of po

171 Oral administration of resveratrol is able to improve glucose homeostasis in ob

172 Interestingly, resveratrol is chemically similar to ICRF-187, a clinica

173 One suggested molecular target of resveratrol is eukaryotic topoisomerase II (topo II), an

174 ynthesis of prenylated stilbenoids, in which resveratrol is prenylated at its C-4 position to form ar

175 We have examined the trans-resveratrol/lipase interaction by quantitative and quali

176 Resveratrol lowered STAT3 acetylation, rescued TSG expre

177 sed on this similarity, we hypothesized that resveratrol may antagonize topo II by a similar mechanis

178 These findings suggest resveratrol may enhance resistance of human lung cells (

179 Resveratrol may play a protective role against the frail

180 ce of OSCC and that combination therapy with resveratrol may provide an attractive means for treating

181 meostasis in obese mice, suggesting that the resveratrol-mediated changes in the gut microbiome may p

182 Resveratrol mediates lowering of blood pressure by parad

183 This suggests that resveratrol might improve the oxidative capacities of ca

184 Resveratrol modifies the lipidomic profile, increases ox

185 ogether, these results provide evidence that resveratrol modulates basal inhibitory synaptic transmis

186 The two NTD-bound resveratrol molecules are principally responsible for pr

187 ere randomized to receive either 150 mg/d of resveratrol (n = 20) or placebo (n = 21) for 6 mo.

188 Interestingly, resveratrol non-monotonically modulates sirtuin signalli

189 Resveratrol nullifies the catalytic activity and redirec

190 ringin (piceatannol-O-glucoside) and piceid (resveratrol-O-glucoside) are incorporated into the ligni

191 Resveratrol oligomers are biologically active polyphenol

192 In order to discover if the resveratrol oligomers can pass the intestinal barrier, t

193 An efficient synthetic route to the resveratrol oligomers quadrangularin A and pallidol is r

194 at the intestinal absorption rate of the two resveratrol oligomers, epsilon-viniferin and hopeaphenol

195 ested effects of periadventitial delivery of resveratrol on all three major pro-restenotic pathologie

196 rein we studied the cytoprotective effect of resveratrol on DEP-exposed human lung cells in a factori

197 Effects of resveratrol on metabolic health have been studied in sev

198 ith a drink with omega-3s, antioxidants, and resveratrol on Mini-Mental State Examination (MMSE) scor

199 the biochemical effects of both ICRF-187 and resveratrol on the human isoforms of topo II, and reveal

200 ion effects of two polyphenols, curcumin and resveratrol, on the aggregation of islet amyloid polypep

201 Resveratrol, on the other hand, directly binds to G3BP1

202 emory abilities were chosen and treated with resveratrol or vehicle for four weeks.

203 Oxidation of the phenolic rings of resveratrol paradoxically leads to oxidative modificatio

204 and quercetin 3-glucoside and the stilbenes resveratrol, piceatannol, astringin and isorhapontin wer

205 s such as melatonin, chloroquine, imiquimod, resveratrol, piceatannol, quercetin, and other flavonoid

206 ersies in the literature and elucidated that resveratrol plays an important activation role by stabil

207 combination of both measures [total dietary resveratrol plus total urinary resveratrol (TDR+TUR)] wa

208 ted for in the wine samples were found to be resveratrol (polyphenolic non-flavonoid) and rutin (flav

209 Resveratrol potentiated GABAA and GABAB-mediated inhibit

210 tenuated secretion while activating SIRT1 by resveratrol-potentiated secretion.

211 Resveratrol pretreatments attenuated cocaine-induced con

212 Taken together, periadventitial delivery of resveratrol produces durable inhibition of all three pro

213 Maternal resveratrol promotes beige adipocyte development in offs

214 Both metformin and resveratrol protected against spontaneous and inflammati

215 ed to analyze Raman spectra with and without resveratrol protection.

216 utions and structural information concerning resveratrol, pterostilbene, and piceids obtained by MSI.

217 Stilbene phytoalexins, namely resveratrol, pterostilbene, piceids and viniferins play

218 n vitro antioxidant activity of tyrosol (T), resveratrol (R) and their acetylated derivatives (AcD),

219 However, the low bioavailability of resveratrol raises questions about whether the antidiabe

220 Anti-oxidant resveratrol reduced DEP-induced ROS production and suppr

221 Together with previous studies showing that resveratrol reduces beta-amyloid toxicity they also give

222 Recent studies have shown that resveratrol regulates dopaminergic transmission and beha

223 nd coumarins) and inhibitors (flavonoids and resveratrol) remains to be determined.

224 he glucoregulatory role of duodenally acting resveratrol required activation of Sirt1 and AMP-activat

225 trocytic cells were pretreated with TIMBD or resveratrol (RES) and then transfected with a plasmid en

226 Resveratrol (RES) has been studied extensively as an ant

227 We previously found that dietary resveratrol (RES) induces beige adipocyte formation in a

228 Resveratrol (RES) is a polyphenol phytoalexin with anti-

229 inding between human serum albumin (HSA) and resveratrol (RES) or its analog (RESAn1) were investigat

230 Resveratrol (RES), a polyphenol found in natural foods,

231 Natural products like resveratrol (RES), and quercetin (QUE) are known free ra

232 f this study is to investigate the impact of resveratrol (RESV) on progression of experimental period

233 ow here that acute intraduodenal infusion of resveratrol reversed a 3 d high fat diet (HFD)-induced r

234 Antioxidants, as resveratrol (RS), may reduce oxidative stress, restore m

235 Resveratrol (RSV) acts either as an antioxidant or a pro

236 Resveratrol (RSV) and nicotinamide (NAM) have garnered c

237 ed the effects of systemic administration of resveratrol (RSV) on the development of experimental per

238 mulations containing the natural antioxidant resveratrol (RSV) were prepared and fully characterized.

239 nd the promoter region of silenced TSG via a resveratrol-sensitive mechanism.

240 Resveratrol significantly counteracted the ROS generatio

241 the pharmacological activation of SIRT1 with resveratrol significantly reduces motor incoordination o

242 anoingredient for functional food, improving resveratrol stability and bioavailability.

243 Resveratrol, staurosporine, and TNF-alpha significantly

244 However, the rapid metabolism of resveratrol strongly limits its bioavailability.

245 onversions and use pharmacokinetic data from resveratrol studies to demonstrate how confusion between

246 as similar to the release profile of infused resveratrol, suggesting strong interactions of infused r

247 Resveratrol supplement sales exceed $30 million annually

248 type 2 diabetes, 5 wk of twice-daily 500 mg-resveratrol supplementation had no effect on GLP-1 secre

249 Here, we evaluated further the effect of resveratrol supplementation of pregnant mice on offsprin

250 study was to investigate the effects of 6-mo resveratrol supplementation on metabolic health outcome

251 Antioxidant/omega-3/resveratrol supplementation was associated with favorabl

252 After 6 mo of resveratrol supplementation, insulin sensitivity was una

253 Chemical SIRT1 activators (SIRT1720 and resveratrol) suppressed the PGE(2)-mediated induction of

254 d genes like senescence-associated proteins, resveratrol synthase, 9s-lipoxygenase, pathogenesis-rela

255 Resveratrol targets the pyruvate dehydrogenase (PDH) com

256 Total dietary resveratrol (TDR) intake was estimated at baseline with

257 total dietary resveratrol plus total urinary resveratrol (TDR+TUR)] was computed with the use of the

258 ethide intermediates to the synthesis of the resveratrol tetramers nepalensinol B and vateriaphenol C

259 The first total synthesis of the resveratrol tetramers vitisin A and vitisin D is reporte

260 The maximum amount of resveratrol that could be dissolved in the oil phase was

261 Natural polyphenols related to resveratrol that have been shown to impact topo II funct

262 tudied age-related factors (i.e., rapamycin, resveratrol, TNF-alpha, and staurosporine), quantitative

263 rophosphate as a prenyl donor and prenylates resveratrol to form arachidin-2.

264 ble-blind, randomized clinical trial, called Resveratrol to Improve Outcomes in Older People With PAD

265 The ability of resveratrol to oxidize cGMP-dependent PKG1alpha (protein

266 re consistent with a strong binding of trans-resveratrol to the CpLIP2 catalytic site via electrostat

267 n, explains the activity restoration role of resveratrol toward some "loose-binding" substrates of SI

268 ing, stability and bioaccessibility of trans-resveratrol (trans-Res).

269 wine consumption, usually ascribed to trans-resveratrol (trans-RSV).

270 while Young's modulus was highly elevated in resveratrol treated DEP-exposed cells.

271 Resveratrol-treated animals also displayed increased net

272 proved learning, memory and mood function in resveratrol-treated animals but impairments in vehicle-t

273 n sensitivity was not affected after 6 mo of resveratrol treatment (adjusted mean Matsuda index: 5.18

274 These results provide novel evidence that resveratrol treatment in late middle age is efficacious

275 Resveratrol treatment of mice with established HF lessen

276 We evaluated the effects of 5 wk of resveratrol treatment on GLP-1 secretion, gastric emptyi

277 a lack of improvement in ejection fraction, resveratrol treatment significantly increased median sur

278 n, and physical activity, were improved with resveratrol treatment.

279 We found trans-resveratrol (tRES) and hesperetin (HESP), at concentrati

280 w that temporary coapplication of the cyclic resveratrol trimer caraphenol A enhances LV gene deliver

281 ious bioactive molecules such as retinol and resveratrol, two ligands with different affinity and bin

282 ant industrial compounds (e.g., artemisinin, resveratrol, vanillin).

283 n and SMC de-differentiation were blocked by resveratrol via its inhibition of the Akt-mTOR pathway.

284 xima region of catechin and epicatechin, and resveratrol was considered.

285 ze on the chemical stability of encapsulated resveratrol was examined by preparing systems with diffe

286 Resveratrol was found to be the most efficient as it tot

287 The thermal behavior of resveratrol was investigated by using simultaneous therm

288 Resveratrol was quantified by U-PLS in both, irrigated a

289 In addition, resveratrol was significantly reduced following heat tre

290 Myricetin and resveratrol were also detected in most of the fruit beer

291 pLIP2 from C. parapsilosis CBS 604 and trans-resveratrol were confirmed with a major contribution of

292 In contrast, resveratrol, which has a low binding affinity for site(s

293 clearly demonstrated for p-coumaric acid and resveratrol, which is associated with many health benefi

294 complexing with mitoxantrone, in contrast to resveratrol, which shows the lowest affinity.

295 cient synthesis of higher-order oligomers of resveratrol will facilitate the biological studies neces

296 n energy transfer from W51 and W350 to trans-resveratrol with a distance of 32 angstrom.

297 iments were used to study the interaction of resveratrol with gliadin and zein.

298 Piceatannol, a stilbene analogue to resveratrol with higher antioxidant activity, was firstl

299 l, suggesting strong interactions of infused resveratrol with the GSP matrix.

300 on of procyanidin B1, caffeic acid and trans-resveratrol, with higher levels compared to those report

301 we have identified an effective analogue of resveratrol, (Z)3,4,5,4'-trans-tetramethoxystilbene (TMS